A Study of Inflammatory Markers in Patients with Alcoholic-Fatty Liver Disease and Non-Alcoholic Fatty Liver Disease
DOI:
https://doi.org/10.61841/sr2gd934Keywords:
Non-alcoholic fatty liver disease, Alcoholic Fatty Liver Disease, Inflammatory MarkersAbstract
Background: Increased levels of various circulating chemicals have been associated with fatty liver disease inflammatory markers. The difference in the level of increased inflammatory markers between patients with AFLD and NAFLD is still unclear. Aims & Objectives: The aim of the present study was to compare the inflammatory markers between patients with alcoholic-fatty liver disease (AFLD) and non-alcoholic fatty liver disease (NAFLD). mterial and method: This descriptive study included 50 individuals with fatty liver disease (25 NAFLD, 25 AFLD). Venous blood samples were taken from fasting patients to assess inflammatory markers (CRP, IL6, TNF α). Statistical analysis was performed using the student’s t- test, with p-values < 0.05 considered significant. Results: The mean values of inflammatory markers (CRP, IL6, TNF-α a) in the NAFLD group were 1.79±0.11, 27.94±1.22, 35.24±2.6, and in the AFLD group, 1.92±0.16, 29.35±1.38, 36.88±2.19. There were no significant changes in CRP, IL6, or TNF-α levels between AFLD patients and those with NAFLD. Conclusion: Fatty liver disease is associated with increased inflammatory markers. Since increased inflammatory markers in fatty liver disease are indicative of liver injury, due importance should be given to the assessment of inflammatory markers in the management of patients with fatty liver disease.
Downloads
References
1. Estes C, Razavi H, Loomba R, Younossi Z, Sanyal AJ. Modeling the epidemic of nonalcoholic fatty liver disease demonstrates an exponential increase in burden of disease. Hepatology2018; 67:123–133.
2. Wong RJ, Cheung R, Ahmed A. Nonalcoholic steatohepatitis is the most rapidly growing indication for liver transplantation in patients with hepatocellular carcinoma in the US. Hepatology2014; 59:2188–2195.
3. Paik JM, Golabi P, Younossi Y, Mishra A, Younossi ZM. Changes in the global burden of chronic liver diseases from 2012 to 2017: the growing impact of NAFLD. Hepatology2020; 72:1605-1616.
4. Younossi ZM, Koenig AB, Abdelatif D, Fazel Y, Henry L, Wymer M. Global epidemiology of nonalcoholic fatty liver disease: meta-analytic assessment of prevalence, incidence, and outcomes. Hepatology 2016; 64:73–84.
5. Polyzos SA, Kountouras J, Mantzoros CS. Obesity and nonalcoholic fatty liver disease: from pathophysiology to therapeutics. Metabolism 2019; 92:82–97.
6. Younossi ZM, Golabi P, de Avila L, Paik JM, Srishord M, Fukui N, et al. The global epidemiology of NAFLD and NASH in patients with type 2 diabetes:
7. Stols-Gonçalves D, Tristão LS, Henneman P, Nieuwdorp M. Epigenetic Markers and Microbiota/Metabolite-Induced Epigenetic Modifications in the Pathogenesis of Obesity, Metabolic Syndrome, Type 2 Diabetes, and Non-alcoholic Fatty Liver Disease. Curr Diabetes Rep (2019) 19(6):31 .
8. Pierantonelli I, Svegliati-Baroni G. Nonalcoholic Fatty Liver Disease: Basic Pathogenetic Mechanisms in the Progression From NAFLD to NASH. Transplantation (2019) 103(1):e1–e13.
9. Friedman SL, Neuschwander-Tetri BA, Rinella M, Sanyal AJ. Mechanisms of NAFLD Development and Therapeutic Strategies. Nat Med (2018) 24(7):908–22.
10. Peng C, Stewart AG, Woodman OL, Ritchie RH, Qin CX. Non-Alcoholic Steatohepatitis: A Review of Its Mechanism, Models, and Medical Treatments. Front Pharmacol (2020) 11:603926.
11. Zhang TS, Qin HL, Wang T, Li HT, Li H, Xia SH et al. Global Publication Trends and Research Hotspots of Nonalcoholic Fatty Liver Disease: A Bibliometric Analysis and Systematic Review. SpringerPlus (2015) 4:776.
12. Bataller R, Brenner DA. Liver fibrosis. Journal of Clinical Investigation. 2005;115(2):209–218.
13. Brundtland GH. Reducing Risks to Health, Promoting Healthy Life. JAMA. 2002;288(16).
14. Walsh K, Alexander G. Alcoholic liver disease. Postgraduate Medical Journal. 2000;76(895):280–286.
15. Wang HJ, Gao B, Zakhari S, Nagy LE. Inflammation in Alcoholic Liver Disease. Annual Review of Nutrition.2012;32(1):343–368.
16. Auguet T, Bertran L, Binetti J, Aguilar C, Martı́nez S, Sabench F, et al. Relationship Between IL-Circulating Levels and TLR2 Hepatic Expression in Women With Morbid Obesity and Nonalcoholic Steatohepatitis. Int J Mol Sci (2020) 21(11):4189.
17. Ponziani FR, Bhoori S, Castelli C, Putignani L, Rivoltini L, Del Chierico F, et al. Hepatocellular Carcinoma is Associated With Gut Microbiota Profile and Inflammation in Nonalcoholic Fatty Liver Disease. Hepatology (2019) 69 (1):107–20.
18. Henao-Mejia J, Elinav E, Jin C, Hao L, Mehal WZ, Strowig T, et al.Inflammasome-Mediated Dysbiosis Regulates Progression of NAFLD and Obesity. Nature (2012) 482(7384):179–85.
19. Stojsavljevic S, Palčić MG, Jukić LV, Duvnjak LS, Duvnjak M. Adipokines and proinflammatory cytokines, the key mediators in the pathogenesis of non-alcoholic fatty liver disease. J Gastroenterol. 2014;20(48):18070–18091.
20. Oruc N, Ozutemiz O, Yuce G, Akarca US, Ersoz G, Gunsar F, et al. Serum procalcitonin and CRP levels in non-alcoholic fatty liver disease: a case control study. BMC Gastroenterol 2009; 9:16.
21. Al-Dahhan NAA, Al-Dahhan HAA. Evaluation of ADA, IL-6, and TNF-alpha levels in type 2 diabetes mellitus: with and without hypoglycemic drugs. Evaluation. 2015;5:7.
22. Nigam P, Bhatt S P, Misra A, Vaidya M, Dasgupta J, Chadha D S. Nonalcoholic fatty liver disease is closely associated with subclinical inflammation: a case-control study on Asian Indians in North India. PLoS ONE 2013; 8:e49286.
23. Targher G, Bertolini L, Rodella S, Lippi G, Franchini M, Zoppini G, et al. NASH predicts plasma inflammatory biomarkers independently of visceral fat in men. Obesity (Silver Spring) 2008;16:1394-9.
24. Nigam P1, Bhatt SP, Misra A, Vaidya M, Dasgupta J, Chadha DS. Nonalcoholic fatty liver disease is closely associated with subclinical inflammation: A case-control study on Asian Indians in North India. J Hepatol 2006;44:1167-74.
25. Oruc N, Ozutemiz O, Yuce G, Akarca US, Ersoz G, Gunsar F, et al. Serum procalcitonin and CRP levels in non-alcoholic fatty liver disease: A case control study. BMC Gastroenterol 2009;9:16.
26. Uchihara M, Izumi N. High-sensitivity C-reactive protein (hs-CRP): A promising biomarker for the screening of non-alcoholic steatohepatitis (NASH). Nihon Rinsho 2006;64:1133-8.
27. Haukeland JW, Damås JK, Konopski Z, Løberg EM, Haaland T, Goverud I, et al. Systemic inflammation in nonalcoholic fatty liver disease is characterized by elevated levels of CCL2. J Hepatol 2006;44:1167-74.
Downloads
Published
Issue
Section
License
This work is licensed under a Creative Commons Attribution 4.0 International License.
You are free to:
- Share — copy and redistribute the material in any medium or format for any purpose, even commercially.
- Adapt — remix, transform, and build upon the material for any purpose, even commercially.
- The licensor cannot revoke these freedoms as long as you follow the license terms.
Under the following terms:
- Attribution — You must give appropriate credit , provide a link to the license, and indicate if changes were made . You may do so in any reasonable manner, but not in any way that suggests the licensor endorses you or your use.
- No additional restrictions — You may not apply legal terms or technological measures that legally restrict others from doing anything the license permits.
Notices:
You do not have to comply with the license for elements of the material in the public domain or where your use is permitted by an applicable exception or limitation .
No warranties are given. The license may not give you all of the permissions necessary for your intended use. For example, other rights such as publicity, privacy, or moral rights may limit how you use the material.
